Applied Dna Sciences Inc (APDN) concluded trading on Thursday at a closing price of $0.17, with 3.95 million shares of worth about $0.67 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.79% during that period and on February 13, 2025 the price saw a loss of about -8.22%. Currently the company’s common shares owned by public are about 55.19M shares, out of which, 51.42M shares are available for trading.
Stock saw a price change of 2.29% in past 5 days and over the past one month there was a price change of -4.55%. Year-to-date (YTD), APDN shares are showing a performance of -14.61% which decreased to -98.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.12 but also hit the highest price of $14.40 during that period. The average intraday trading volume for Applied Dna Sciences Inc shares is 5.38 million. The stock is currently trading -2.64% below its 20-day simple moving average (SMA20), while that difference is down -8.12% for SMA50 and it goes to -77.42% lower than SMA200.
Applied Dna Sciences Inc (NASDAQ: APDN) currently have 55.19M outstanding shares and institutions hold larger chunk of about 38.64% of that.
The stock has a current market capitalization of $9.61M and its 3Y-monthly beta is at 0.38. It has posted earnings per share of -$6.89 in the same period. It has Quick Ratio of 3.17 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APDN, volatility over the week remained 8.32% while standing at 8.28% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on February 12, 2021 offering a Buy rating for the stock and assigned a target price of $24 to it. Coverage by H.C. Wainwright stated Applied Dna Sciences Inc (APDN) stock as a Buy in their note to investors on January 14, 2021, suggesting a price target of $14 for the stock. On December 18, 2020, H.C. Wainwright Reiterated their recommendations, while on July 20, 2020, H.C. Wainwright Reiterated their ratings for the stock with a price target of $22. Stock get a Buy rating from H.C. Wainwright on July 02, 2020.
